Doer Bio Secures Fifth Consecutive Spot on Hangzhou's Prestigious Unicorn-Track List Amid IPO Filing

On the afternoon of April 24, 2025, the ninth Everything Grows Conference, hosted by the Zhejiang Provincial Committee of the China Democratic建国会 (Minjian), Zhejiang Federation of Industry and Commerce, and China Investment Development Promotion Association, was held in Hangzhou. At the conference, the Hangzhou Venture Capital Association, Weilian, and Hangzhou Bank jointly released the "2025 Hangzhou Unicorn and Quasi-Unicorn Enterprise List."Zhejiang Doer Biologics Co., Ltd. Again Ranks on the List of Hangzhou's Near-Unicorn Enterprises.

This list includes a total of 125 quasi-unicorn companies in the healthcare sector, with Doer Biologics making the list for the fifth time. Quasi-unicorns refer to companies valued at over 100 million US dollars, demonstrating rapid growth, relative scarcity, and the potential to grow into unicorn companies within a short period. Being selected for the list for five consecutive years is continuous recognition of Doer Biologics' tremendous development potential in the innovative biopharmaceutical field, as well as encouragement for the company’s dedication to its original mission and commitment to research and innovation over the years.

Currently, Doer Biologics has successfully advanced five innovative drug projects into the clinical research stage. In the future, Doer Biologics will continue to focus on the research of multi-specificity innovative biologics based on multi-domain structures, continuously developing innovative biologics with proprietary intellectual property rights to address unmet clinical needs. Meanwhile, adhering to the rigorous "DOER" scientific spirit, with the corporate vision of contributing to human health through diligent and innovative work, the company is dedicated to the development of novel biologic drugs. Through the team's incremental efforts, Doer Biologics aims to contribute to human health!